Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population.
Allavena
C
C
Mounoury
O
O
Rodallec
A
A
Reliquet
V
V
Billaud
E
E
Raffi
F
F
D000328:Adult; D000368:Aged; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000009:adverse effects*; D000068898:Raltegravir Potassium; D019438:Ritonavir / Q000009:adverse effects*; D016896:Treatment Outcome
D017320:HIV Protease Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D019438:Ritonavir